Document is current
Any future updates will be listed below
-
Authors
Warren, Richard B.
Donnelly, Kerry
Kiri, Sandeep
Taieb, Vanessa
Slim, Mahmoud
Fahrbach, Kyle
Neupane, Binod
Betts, Marissa
Armstrong, April https://orcid.org/0000-0003-0064-8707
-
Funding
Funding for this research was provided by:
UCB
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 22 October 2024
First Online: 1 November 2024
Declarations
:
: Richard B. Warren declares receiving consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly and Company, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi and UCB Pharma. He also declares receiving research grants to his institution from AbbVie, Almirall, Janssen, LEO Pharma, Novartis and UCB Pharma, and honoraria from Astellas, DiCE, GSK and Union Therapeutics. Richard B. Warren is an Editor-in-Chief of<i> Dermatology and Therapy</i>. Richard B. Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kerry Donnelly, Sandeep Kiri, Vanessa Taieb are employees and shareholders of UCB Pharma. Mahmoud Slim, Kyle Fahrbach, Marissa Betts, Binod Neupane are employed by Evidera, a part of Thermo Fisher Scientific. April Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI, Incyte, Janssen, LEO Pharma, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sun Pharma, Sanofi and UCB Pharma.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
